ATAI Life Sciences AG Revenue and Competitors

Claim your profile

Berlin, Germany



Total Funding



Estimated Revenue & Valuation

  • ATAI Life Sciences AG's estimated annual revenue is currently $21.2M per year.(i)
  • ATAI Life Sciences AG's estimated revenue per employee is $155,000
  • ATAI Life Sciences AG's total funding is $347.1M.
  • ATAI Life Sciences AG's current valuation is $2B.

Employee Data

  • ATAI Life Sciences AG has 137 Employees.(i)
  • ATAI Life Sciences AG grew their employee count by 12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Who we are: ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. Our mission: We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. Our approach: By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





ATAI Life Sciences AG News

2022-04-17 - Noxxon Reports 2021 Financial Results

Gregory Weaver, CFO of atai Life Sciences, with over 25 years in the life ... the Group – NOXXON Pharma N.V. and NOXXON Pharma AG – has not...

2022-04-06 - Christian Angermayer Buys 1 Million Shares Of Atai Life, His Own Company - Benzinga

“Many #biotech stocks are cheap at the moment. In my opinion, Atai Life Sciences AG stands out though for two reasons: the size of the market (...

2022-03-22 - The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For

Among noteworthy developments in the space, Novartis AG NVS announced the FDA nod ... Atai Life Sciences N.V. ATAI (before the market open)

2021-08-12 - Pe­ter Thiel-backed ATAI launch­es new Salvia-fo­cused biotech; Pur­due bank­rupt­cy tri­al ex­pect­ed to be­gin to­day — re­port

ATAI Life Sci­ences, the Pe­ter Thiel-backed um­brel­la de­vel­op­er of psy­che­delics and oth­er drugs for men­tal health con­di­tions, launched a new port­fo­lio com­pa­ny Thurs­day. The new out­fit is called Re­vix­ia Life Sci­ences, and its mis­sion is to bring the main ac­tive in­gre­di­en ...

2021-04-22 - Peter Thiel's psychedelic drug startup Atai eyes $100M IPO

Peter Thiel (Neilson Barnard/Getty Images) Investor interest in psychedelic-based medicine has increased over the last several years amid growing support from regulators, clinicians and patients. In the latest move in the space, Atai Life Sciences, a Peter Thiel-backed startup that is developin ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding